Results 31 to 40 of about 5,953 (226)

Recent advances in managing chronic HCV infection: Focus on therapy in patients with severe liver disease [PDF]

, 2016
Chronic hepatitis C virus (HCV) infection still represents a major public health problem, as it is thought to be responsible for more than 350,000 deaths around the globe on a yearly basis.
Maan, R. (Raoel), Meer, A.J.P. (Adriaan) van der   +1 more
core   +5 more sources

Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study [PDF]

, 2017
Background: Since direct-acting antivirals (DAAs) have been approved for the treatment of hepatitis C virus (HCV) infection, a small series of patients with new-onset neuropsychiatric alterations have been referred to us.
Amodio, Piero, Burra, Patrizia, De Rui, Michele, Ferrarese, Alberto, Gambato, Martina, Germani, Giacomo, Montagnese, Sara, Russo, Francesco Paolo, Senzolo, Marco, Turco, Matteo, Volpato, Sofia, Zanetto, Alberto   +11 more
core   +1 more source

Direct Acting Antivirals Which Is Effective in Pan-genotypic Chronic Hepatitis C Patients with or without Liver Cirrhosis

The Korean Journal of Gastroenterology, 2016
Articles: Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection (N Engl J Med 2015;373:2599-2607) Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection (N Engl J Med 2015;373:2608-2617)
Ki Tae Yoon
doaj   +1 more source

Combination of Direct Antiviral Therapy in Hepatitis C Patients, Population of Karachi

Pakistan Journal of Medicine and Dentistry, 2020
Background: Pakistan has approximately eight million Hepatitis C Virus (HCV) infected patients. Initial regimen of interferon-based along with ribavirin showed SVR (Sustained Virological Response Rate) of up to 50%.
Samia Perwaiz Khan, Muslim Abbas, Ajeet Kumar, Fadieleh A. Sohail, Rubina Ghani   +4 more
doaj   +1 more source

Effectiveness and safety of sofosbuvir‐based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis: results of a multicenter real‐life cohort [PDF]

, 2016
[Abstract] Patients with HCV genotype 3 (GT3) infection and cirrhosis are currently the most difficult to cure. We report our experience with sofosbuvir+daclatasvir (SOF+DCV) or sofosbuvir/ledipasvir (SOF/LDV), with or without ribavirin (RBV) in clinical
Alonso, S., Ampuero, J., Badia, E., Baliellas, C., Buti, M., Carrión, J.A., Castro-Iglesias, Ángeles, Devesa, M.J., Esteban, R., Fernández, I., Fernández-Carrillo, C., Fernández-Rodríguez, C.M., Gea, F., Granados, R., Gómez, A., Lens, S., Llerena, S., Montero, J.L., Olveira, A., Pascasio, J.M., Planas, J.M.M., Polo, B., Real, Y., Rincón, D., Riveiro-Barciela, M., Rubín, A., Salmerón, J., Turnes, J.   +27 more
core   +2 more sources

Efectividad del tratamiento de la hepatitis C en pacientes atendidos en la consulta de atención farmacéutica

Ars Pharmaceutica, 2020
RESUMEN Objetivos: Determinar la efectividad del tratamiento de la hepatitis C crónica definida como la respuesta viral sostenida a las 12 semanas (RVS12) tras la finalización del tratamiento con fármacos antivirales de acción directa (AAD ...
José Miguel Sotoca-Momblona, Montserrat Rodriguez-Reyes, Neus Pagès-Puigdemont, Concepció Bartres-Viñas, Sergio Rodriguez-Tajes, Sabela Lens-García, Zoe Mariño-Mendez   +6 more
doaj   +1 more source

Use of glecaprevir and pibrentasvir as rescue therapy in patients with resistance to direct-acting antiviral agents

Annals of Hepatology, 2022
Introduction and Objective: Hepatitis C virus infection is one of the main causes of chronic liver disease. Treatment with direct-acting antivirals (DAAs) has shown high efficacy in achieving sustained viral response with a low risk of relapse. There are
LS Juarez Chavez, JS Sandoval Mendoza
doaj   +1 more source

NS5A Resistance-Associated Substitutions in Patients with Genotype 1 Hepatitis C Virus:Prevalence and Effect on Treatment Outcome [PDF]

, 2017
Background & Aims The efficacy of NS5A inhibitors for the treatment of patients chronically infected with hepatitis C virus (HCV) can be affected by the presence of NS5A resistance-associated substitutions (RASs).
Brainard, Diana M, Chuang, Wan-Long, Doehle, Brian, Dore, Gregory J, Dvory-Sobol, Hadas, Han, Kwang-Hyub, Hedskog, Charlotte, Jacobson, Ira, Knox, Steven, Mangia, Alessandra, Martin, Ross, McHutchison, John G, Miller, Michael D., Mizokami, Masashi, Mo, Hongmei, Pianko, Stephen, Sulkowski, Mark, Svarovskaia, Evguenia, Yun, Chohee, Zeuzem, Stefan   +19 more
core   +2 more sources

New perspectives for preventing hepatitis C virus liver graft infection [PDF]

, 2016
publisher: Elsevier articletitle: New perspectives for preventing hepatitis C virus liver graft infection journaltitle: The Lancet Infectious Diseases articlelink: http://dx.doi.org/10.1016/S1473-3099(16)00120-1 content_type: article copyright: © 2016 ...
Abdelmalek, Adam, Akazawa, Andre, Audrey Coilly, Bandiera, Bankwitz, Baumert, Benedicto, Berenguer, Berenguer, Berenguer, Berenguer, Bizollon, Blasco, Brown, Bzowej, Carrion, Carrion, Carrion, Chalasani, Charlton, Charlton, Charlton, Charlton, Chung, Ciesek, Coilly, Coilly, Coilly, Colpitts, Colpitts, Crespo, Curry, Curry, Daniel J Felmlee, Davis, de Jong, Denniston, Desombere, Deuffic-Burban, Didier Samuel, Fafi-Kremer, Faisal, Fauvelle, Feld, Felmlee, Firpi, Fofana, Fofana, Fofana, Forman, Forns, Forns, Foster, Foster, Fukasawa, Fukuhara, Gambato, Gane, Gane, Gerold, Guedj, Haberstroh, Haid, He, Helle, Hopcraft, Janssen, Ji, Jiang, Keck, Khan, Kim, Kong, Kugelmas, Kwo, Kwo, Lanford, Law, Leroy, Lin, Lupberger, Mailly, Manns, Manns, Marino, Martin, Martin, Masaki, Mazzaferro, Meuleman, Meuleman, Meuleman, Munoz, O'Shea, Ojo, Ouwerkerk-Mahadevan, Owsianka, Pawlotsky, Perin, Picciotto, Ploss, Ploss, Poordad, Prieto, Pungpapong, Raymond T Chung, Reddy, Roche, Rowe, Rowe, Sainz, Shergill, St Vincent, Sugawara, Sulkowski, Takaki, Terrault, Thomas F Baumert, Toso, Uprichard, Van Der Ree, Vanwolleghem, Veldt, Vercauteren, Vercauteren, von Hahn, Walter, Wang, Watt, Wedemeyer, Welker, Xiao, Xiao, Xirouchakis, Yamashita, Zahid, Zeisel, Zeisel, Zhang, Zhang, Zhu, Zona   +143 more
core   +4 more sources

Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: A systematic review and meta-analysis

Journal of Infection and Public Health, 2018
Velpatasvir is a newly FDA-approved inhibitor of hepatitis C virus (HCV) NS5A protein. We performed this systematic review and meta-analysis to investigate the safety and efficacy of velpatasvir plus sofosbuvir in the treatment of chronic HCV infection ...
Hussien Ahmed, Abdelrahman I. Abushouk, Attia Attia, Mohamed Gadelkarim, Mohamed Gabr, Ahmed Negida, Mohamed M. Abdel-Daim   +6 more
doaj   +1 more source